

ESPS Peer-review Report
Name of Journal: World Journal of Clinical Cases

ESPS Manuscript NO: 11689

Title: New targeted therapies for breast cancer: how is Breast Cancer treated?

Reviewer code: 02446383

Science editor: Fang-Fang Ji

Date sent for review: 2014-05-30 19:49

Date reviewed: 2014-06-12 11:35

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

1. Recommend to condense the paper and to characterize the breast cancer treatment based on the current breast cancer molecular classification (Luminal type, Her2 type, triple-negative/basal like) 2. Currently triple negative (TN) breast cancer is therapeutically challenging due to lack of molecular targets. Many related studies are under investigation. Rb/p16 pathway abnormality and p53 mutation play roles in poor prognosis of TN cancer, which may contribute to the development of targeted therapy for TN cancer patients. Two recently published articles demonstrated expression of p16 and p53 in TN breast cancer and discussed the two biomarkers' potential role for being a target candidate. This manuscript did not include them. #Ki-67 Expression is Increased in p16 Expressing Triple-negative Breast Carcinoma and Correlates with p16 only in p53-negative Tumors. Human Pathology. 2014 Apr;45(4):802-9 #Roles of p53 and p16 in Triple-negative Breast Cancer, Breast Cancer Management (Future Medicine). 2013;2:537-544 3. Page 15, ref #158 needs to be updated. The updated Her2 guidelines published in 2013 is as follows: Arch Pathol Lab Med. Doi:10.5858/arpa.2013-0953-SA. The Her2 related statement on the page 15 needs to be revised accordingly. 4. In the first sentence of the second paragraph of "I-Introduction", there is a minor grammar error: "The breast microenvironment consists of"